HLA Class I Allele Frequencies in Southern Iranian Women with Breast Cancer

Document Type : Original Article


1 Shiraz Institute for Cancer research, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

2 Shiraz Institute for Cancer research, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran Department of Immunology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran


Hildesheim A, Wang SS. Host and viral genetics and risk of cervi
cal cancer: a review. Virus Res 2002; 89:229-240.
2. Hassen E, Nahla G, Bouaouina N, Chouchane L. The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk. Mol Biol Rep 2010; 37:119-126.
3. Nagata Y, Hanagiri T, Mizukami M, Kuroda K, Shigematsu Y, Baba T,
et al
Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer 2009; 65:91-97.
4. Ghaderi A, Talei A, Gharesi-Fard B, Farjadian Sh, Amirzargar A, Vasei M. HLA-DRB1 allele and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res 2001; 7:39-41.
5. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DH, isselbacher KJ,
et al
. Genetic susceptibility to breast cancer: HLA DQ*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci USA 2000; 97:11451-1154.
6. Gourley C, Thornton C, Massie C, Prescott RJ, Turner M, Leonard RC,
et al
. Is there a relationship between HLA type and prognostic factors in breast cancer? Anticancer Res 2003; 23:633-638.
7. Lavado R, Benavides M, Villar E, Ales I, Alonso A, Caballero A. The HLA-B7 allele confers susceptibility to breast cancer in Spanish women. Immunol Lett 2005; 101:223–225.
8. Yokoe T, Ishida T, Ogawa T, Iino Y, Izuo M. Relationship of breast cancer and HLA in Japanese females. Gan No Rinsho 1990; 36:26- 33.
9. Wu MS, Hsieh RP, Huang SP, Chang YT, Lin MT, Chang MC,
et al
. Association of HLA-DQB1(*)0301 and HLA-DQB1(*)0602 with different subtypes of gastric cancer in Taiwan. Jpn J Cancer Res 2002; 93:404-10.
10. Ryschin E, Autschbach F, Eisold S, Klar E, Buchler MW, Schmidt J. Expression of HLA class I/II antigens and T cell immune response in human neuroendocrine tumors of the pancreas. Tissue Antigens 2003; 62:48-54.
11. Hiraki A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H,
et al
. High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines. Anticancer Res 2004; 24:1525-8.
12. Belov K. The role of the Major Histocompatibility Complex in the spread of contagious cancers. Mamm Genome 2011; 22:83–90.
13. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Human Immunol 2000; 61:65-73.
14. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008; 20:343-52.
15. Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L,
et al
. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Int J Cancer 2000; 87:553-558.
16. Bettinotti MP, Norris RD, Hackett JA, Thompson CO, Simonis TB, Stroncek D,
et al
. Frequency of human leukocyte antigen-A24 alleles in patients with melanoma determined by human leukocyte antigen-A sequence-based typing. J Immunother 2000; 23:282-287.
17. Matsuda K, Tsunoda T, UmanoY, Tanimuta H, Nukaya L, Takesako K,
et al
. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004; 53:609-616.
18. Hao X, Shao Y, Ren X, Liu H, Xu Q, Li H,
et al
. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/ A24(+) gastrointestinal cancer patients. J Cancer Res Clin Oncol 2002; 128:507-515.
19. Kumamaru W, Nakamura S, Kadena T, Yamada A, Kawamura E, Sasaki M,
et al
. T-cell receptor V beta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma. Int J Cancer 2004; 108:686-695.
20. Eura M, Chikamatsu K, Katsura F, Obata A, SabaoY, Takiguchi M,
et al
. A wild-type sequence P53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinoma of the head and neck. Clin Cancer Res 2000; 6:979-986.
21. Ferries E, Connan F, Pages F, Gaston J, Hagnere AM, Vieillefond A,
et al
. Identification of p53 peptides recognized by CD8 (+) T lymphocytes from patients with bladder cancer. Hum Immunol 2001; 62:791-798.
22. Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P,
et al
. Identification of a novel immunogenic HLA-A*0201- binding epitope of HER-2/neu with potent antitumor properties. J Immunol 2008; 181:146-154.
23. Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T,
et al
. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17:3408-3419.
24. Zhao M, Cai H, Li X, Zheng H, Yang X, Fang W,
et al
. Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese. J Transl Med 2012; 10:57.
25. Nitta T, Ebato M, Sato K. Association of malignant glioma with the human leukocyte antigen, HLA-A24(9). Neurosurg Rev 1994; 17:211-215.
26. Ishikawa K, Nakano H, Tsukamoto, Fujioka T, Nagakubo I. Testicular cancer in father and son. Int J Urol 1996; 3:0-3.
27. Machens A, Löliger C, Pichlmeier U, Emskötter Th, Busch C, Izbicki JR. Correlation of thymic pathology with HLA in Myasthenia Gravis. Clin Immunol 1999; 91:296-301.
28. Wei L, Xiao LL, Wu XY, Lin Q, Dong M, Wen JY,
et al
. Expression and analysis of HLA-A, B and DRB1 genes in patients with chronic myelogenous leukemia in Guangdong area. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16:915-918.
29. Hiraki A, Ikeda K, Yoshino T, Kaneshige T, Kiura K, Kunisada T,
et al
. Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele. Biochem Biophys Res Commun 2001; 286:786-791.
30. Adamashvili IM, Fraser PA, McDonald JC. Association of serum concentration of soluble class I HLA with HLA allotypes. Trasplantation 1996; 61:984-987.
31. Shimura T, Hagihara M, Yamamoto K, Takebe K, Munkhbat B, Ogoshi K,
et al
. Quantification of serum-soluble HLA class I antigens patients with gastric cancer. Hum Immunol 1994; 40:183- 186.
32. Zavazava N, Wobst B, Ferstl R, Muller-Ruchholtz W. Soluble MHC class I molecules in human body fluids. J Clin Lab Anal 1994; 8:432-436.
33. Spaggriari MG, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F,
et al
. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptor through FASL-FAS interaction. Blood 2002; 100:4098-4107.
34. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G,
et al
. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes. Int Immunol 2000; 12:195-203.
35. Yamazoe S, Tanaka H, Iwauchi T, Yoshii M, Ito G, Amano R,
et al
. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Pancreas 2011; 40:896-904.
36. Iwauchi T, Tanaka H, Yamazoe S, Yashiro M, Yoshii M, Kubo N,
et al
. Identification of HLA-A*2402-restricted epitope peptide derived from ERas oncogene expressed in human scirrhous gastric cancer. Cancer Sci 2011; 102:683-689.
37. Park KS, Park MH, Juji T, Tokunaga K. Complement C4A, C4B and BF haplotype in Koreans. Tissue Antigens 1996; 47:200-205.
38. Tokunaga K, Zhang WJ, Christiansen FT, Dawkins RL. The genomic structure of two ancestral haplotype carrying C4A duplications. Immunogenetics 1991; 34:247-51.